We are live on ! Find out more
TCM

Tamarack Capital Management Portfolio holdings

AUM $840M
1-Year Est. Return 19.47%
This Fund
S&P 500
This Quarter Est. Return
+17.08%
1 Year Est. Return
+19.47%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$378M
AUM Growth
+$199M
Cap. Flow
+$168M
Cap. Flow %
44.51%
Top 10 Hldgs %
63.15%
Holding
34
New
10
Increased
13
Reduced
9
Closed
2

Top Buys

Rank Stock Value
1
DGX icon
Quest Diagnostics
DGX
+$22.4M
2
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$9.03M
3
CFN
CAREFUSION CORPORATION
CFN
+$8.4M
4
EW icon
Edwards Lifesciences
EW
+$7.88M
5
NTUS
Natus Medical Inc
NTUS
+$5.86M

Top Sells

Rank Stock Value
1
HAE icon
Haemonetics
HAE
+$9.3M
2
AGN
Allergan Inc
AGN
+$8.53M
3
PCRX icon
Pacira BioSciences
PCRX
+$6.34M
4
ITGR icon
Integer Holdings
ITGR
+$3.2M
5
MDAS
MEDASSETS INC COM STK (DE)
MDAS
+$3.16M

Sector Composition

Rank Sector Weight
1 Healthcare 46.46%
2 Technology 2.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$101M 26.69%
+600,000
New +$101M
DGX icon
2
Quest Diagnostics
DGX
$25.1B
$23.2M 6.14%
+375,000
New +$22.4M
ALKS icon
3
Alkermes
ALKS
$8.82B
$21M 5.56%
625,000
+75,000
+14% +$2.44M
PCRX icon
4
Pacira BioSciences
PCRX
$1.02B
$18M 4.77%
375,000
-173,900
-32% -$6.34M
ITGR icon
5
Integer Holdings
ITGR
$3.35B
$14M 3.69%
449,770
-98,730
-18% -$3.2M
VPHM
6
DELISTED
VIROPHARMA INC
VPHM
$13.7M 3.64%
350,000
+25,000
+8% +$817K
VOLC
7
DELISTED
VOLCANO CORPORATION COM STK
VOLC
$13M 3.45%
544,050
+224,607
+70% +$4.78M
SPNC
8
DELISTED
Spectranetics Corp
SPNC
$12.3M 3.25%
730,000
+330,373
+83% +$5.76M
AGN
9
CALL
DELISTED
Allergan Inc
AGN
$11.3M 2.99%
+125,000
New +$11.2M
MDAS
10
DELISTED
MEDASSETS INC COM STK (DE)
MDAS
$11.2M 2.96%
440,000
-141,094
-24% -$3.16M
TEVA icon
11
CALL
Teva Pharmaceuticals
TEVA
$35.9B
$10.2M 2.7%
270,000
+70,000
+35% +$2.73M
XLV icon
12
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$42.1B
$10.1M 2.68%
+200,000
New +$10M
COV
13
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
$10.1M 2.66%
165,000
+46,560
+39% +$2.84M
ATRC icon
14
AtriCure
ATRC
$1.77B
$9.88M 2.62%
900,000
+27,553
+3% +$272K
AUXL
15
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$9.55M 2.53%
525,000
+500,000
+2,000% +$9.03M
VAR
16
DELISTED
Varian Medical Systems, Inc.
VAR
$9.34M 2.47%
142,548
+11,404
+9% +$722K
DXCM icon
17
DexCom
DXCM
$27.6B
$9.22M 2.44%
1,307,176
-92,824
-7% -$588K
NTUS
18
DELISTED
Natus Medical Inc
NTUS
$8.35M 2.21%
589,080
+437,936
+290% +$5.86M
CFN
19
DELISTED
CAREFUSION CORPORATION
CFN
$8.3M 2.2%
+225,000
New +$8.4M
SRGA
20
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$8.23M 2.18%
73,333
+1,271
+2% +$144K
PRGO icon
21
Perrigo
PRGO
$1.4B
$8.14M 2.16%
66,000
+11,000
+20% +$1.37M
VCRA
22
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$7.91M 2.09%
425,000
-47,105
-10% -$767K
EW icon
23
Edwards Lifesciences
EW
$47.6B
$7.81M 2.07%
+673,200
New +$7.88M
LH icon
24
Labcorp
LH
$24.3B
$3.97M 1.05%
46,560
-29,100
-38% -$2.45M
BRKR icon
25
Bruker
BRKR
$9.2B
$3.61M 0.96%
175,000
-25,000
-13% -$478K
1
2

Similar funds

RI
Relational Investors San Diego, California $840M AUM 0.57% 1-Year Est. Return
CWA
Constellation Wealth Advisors New York $903M AUM 2.38% 1-Year Est. Return
GHF
Good Harbor Financial Barrington, Illinois $916M AUM 5.96% 1-Year Est. Return
F
FutureAdvisor San Francisco, California $617M AUM 6.57% 1-Year Est. Return
TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
BMCMI
Bryn Mawr Capital Management Inc Bryn Mawr, Pennsylvania $577M AUM 6.5% 1-Year Est. Return
GACM
Green Arrow Capital Management New York $535M AUM 14.21% 1-Year Est. Return
AH
Achievement Holdings Chicago, Illinois $1.2B AUM 9.2% 1-Year Est. Return

Tamarack Capital Management's Q3 2013 Portfolio in Review

As of Q3 2013, Tamarack Capital Management held 34 positions worth $378M, up 112% from $179M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Tamarack Capital Management deployed $168M of net new capital in Q3 2013, opening 10 new positions and adding to 13 existing holdings. Its largest new stake was Quest Diagnostics: 375,000 shares worth $23.2M.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 70% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Pacira BioSciences, an estimated $6.34M trimmed.

  • Tamarack Capital Management's largest Q3 2013 buy was Quest Diagnostics: 375,000 shares worth $23.2M.
  • Tamarack Capital Management added most to AUXILIUM PHARAMCEUTICALS INC in Q3 2013, an estimated $9.03M increase.
  • Tamarack Capital Management's biggest Q3 2013 reduction was Pacira BioSciences, cutting an estimated $6.34M.
  • Tamarack Capital Management fully exited Haemonetics in Q3 2013, selling an estimated $9.3M.
  • Tamarack Capital Management's ten largest holdings make up 63% of its $378M portfolio in Q3 2013.
  • Tamarack Capital Management opened 10 new positions and closed 2 in Q3 2013.
  • Tamarack Capital Management's portfolio value rose 112% quarter-over-quarter to $378M.

Based on Tamarack Capital Management's 13F filing for Q3 2013, filed 7 Nov 2013.